AstraZeneca

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.

IRLAB Therapeutics CEO Kristina Torfgård discusses the company's five drug candidates for Parkinson's disease, including mesdopetam for levodopa-induced dyskinesias, pirepemat for balance and falls, and IRL1117 as a potential levodopa replacement. The proprietary Integrative Screening Process (ISP) platform, based on advanced preclinical models and AI, significantly enhances drug discovery success rates.

Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Accord, Applied, Astrazeneca, Azitra, Briacell, Glycomine, Imcheck, Merck, Moderna, Nicox, Novartis, Valneva.

FDA approves AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis, supported by Phase III MANDARA trial data showing non-inferiority to GSK's Nucala. Fasenra offers a 59% remission rate and allows more patients to taper off corticosteroids.

AstraZeneca's Fasenra receives FDA approval for EGPA treatment in the US, based on the MANDARA Phase 3 trial. Fasenra showed comparable efficacy to mepolizumab, with 60% remission rate and 41% OCS taper success.

AstraZeneca's Fasenra approved in the US for EGPA, based on MANDARA trial results showing efficacy vs. mepolizumab. Fasenra offers a new treatment option, potentially reducing steroid dependency.

The Liberal National Coalition believes in Australia's life sciences and biotech sector's potential, highlighting strengths like health research, clinical trials, and biotech companies. The speaker criticizes current Labor Government policies for hindering sector growth, citing funding cuts and anti-business policies. They advocate for a Coalition approach focusing on commercializing research, attracting private investment, leveraging sector strengths, and avoiding picking winners, as demonstrated in past policies like the Medical Research Future Fund and National Innovation and Science Agenda.

FDA approves Fasenra (benralizumab) for EGPA, based on MANDARA trial showing it as effective as Nucala in inducing remission and reducing steroid use. Fasenra, developed by AstraZeneca, is administered monthly via subcutaneous injection and is priced at $5,511.41 per dose, with average out-of-pocket cost of $46 for insured patients.

AstraZeneca’s Fasenra met primary endpoint in MANDARA trial, showing non-inferiority to GSK’s Nucala for EGPA, a rare vasculitis. Both drugs target eosinophils and are under investigation for multiple conditions. GlobalData forecasts comparable sales by 2029.